[Animal models of neurodegenerative diseases].
Numerous evidences indicate that the phenotype of a neurodegenerative disease and its pathogenetic mechanism are only loosely linked. The phenotype is directly related to the topography of the lesions and is reproduced whatever the mechanism as soon as the same neurons are destroyed or deficient: the symptoms of Parkinson disease are mimicked by any destruction of the neurons of the substantia nigra, caused for instance by the toxin MPTP. This does not mean that idiopathic Parkinson disease is due to MPTP. In the same way, mouse lines such as Reeler, Weaver and Staggerer in which ataxia occurs spontaneously does not help to understand human ataxias: now that mutations responsible for these phenotypes have been identified, it appears that one is responsible for lissencephaly (mutation of the reelin gene) and the other two have no equivalent in man. Therapeutic attempts, however, rely on the understanding of the pathogenetic mechanisms. Introducing a mutated human transgene in the genome of an animal has, in many instances, significantly improved this understanding. Transgenic mice have proven useful in reproducing lesions seen in neurodegenerative disease such as the plaques of Alzheimer disease (in the APP mouse which has integrated the mutated gene of the amyloid protein precursor), the tau glial and neuronal accumulation (seen in cases of frontotemporal dementias due to tau mutation), the nuclear inclusions caused by CAG triplet expansion (seen in the mutation of Huntington disease and autosomal dominant spinocerebellar ataxias). These recent advances have fostered numerous therapeutic attempts. Transgenesis in drosophila and in the worm Caenorhabditis elegans have opened new possibilities in the screening of protein partners, modifier genes, and potential therapeutic molecules. However, it is also becoming clear that introducing a human mutated gene in an animal does not necessarily trigger pathogenetic cascades identical to those seen in the human disease. Human diseases have to be studied in parallel with their animal models to ensure that the model mimic at least a few original mechanisms, on which new therapeutics may be tested.
Langui
Dominique
D
Laboratoire de Neuropathologie Raymond Escourolle, Hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
Lachapelle
François
F
Duyckaerts
Charles
C
D000544:Alzheimer Disease / Q000235:genetics; D016229:Amyloid beta-Peptides / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D000818:Animals; D030801:Animals, Genetically Modified; D001259:Ataxia / Q000235:genetics; D017173:Caenorhabditis elegans / Q000235:genetics; D003704:Dementia / Q000235:genetics; D004195:Disease Models, Animal; D004331:Drosophila melanogaster / Q000235:genetics; D018390:Gene Targeting; D005808:Genes, Recessive; D020271:Heredodegenerative Disorders, Nervous System / Q000235:genetics; D006801:Humans; D020961:Lewy Body Disease / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D008818:Mice, Neurologic Mutants; D018598:Minisatellite Repeats; D019636:Neurodegenerative Diseases / Q000139:chemically induced; D009498:Neurotoxins / Q000633:toxicity; D020734:Parkinsonian Disorders; D017096:Prion Diseases / Q000235:genetics; D000091042:Reelin Protein; D013045:Species Specificity; D051844:alpha-Synuclein / Q000235:genetics / Q000378:metabolism; D016875:tau Proteins / Q000172:deficiency / Q000235:genetics / Q000502:physiology
D016229:Amyloid beta-Peptides; D009498:Neurotoxins; D000091042:Reelin Protein; D051844:alpha-Synuclein; D016875:tau Proteins; C000717127:RELN protein, human; C000717128:Reln protein, mouse